Cancer – detected early, precisely monitored & actively managed

  • Revolutionary cancer diagnostics at the forefront of cfDNA technology & bioinformatics
  • Earliest detection of the appearance or re-appearance of cancer
  • Active cancer management – early response to treatment & map active mutations over time



Chronix Biomedical has now made available a laboratory developed test for the detection of risk factors highly associated with cancer. Through the simple process of drawing blood, we can now offer a test that can, with a high degree of accuracy, detect macromolecular mutations of DNA fragments in blood plasma, which are closely associated with cancer.

The Chronix Biomedical Cancer Evaluation blood test is a vast improvement to more traditional methods of determining the presence of cancer. The essential difference is that now for the first time, using proprietary Next Generation Genomic Sequencing we can detect cancer mutations of DNA in blood plasma. Advantages of this new technology, also referred to as Liquid Biopsy, is that we can now look at the entirety of the body and its health state relating to cancer. Current scanning and tissue biopsy can only look at a specific part of the body, such as the lung or prostate, and is usually only carried out on presentation of symptoms.

With Chronix Biomedical’s blood test we can now usefully evaluate asymptomatic clients when suspected being at high risk for developing cancer, for example individuals that smoke or have a genetic mutation in their family. This in most cases provides reassurance that all is well, however, in the event of a positive result, action can be taken and clients signposted to relevant specialists. Early detection of any cancer is vital to increasing the chance of a positive outcome.

For those with concerns specifically about breast, prostate or colorectal cancers, or those that are seeking clarity of their cancer risk generally, the Chronix blood test can provide you with an evaluation that allows the Doctor to make a more informed decision on further action.

CNI Explanation – What is NGS?

Next Generation Sequencing (NGS) is a method which allowed scientists to determine the sequence of the whole human Genome, and such DNA „mapping” can now be performed on circulating cell DNA in the blood – either from circulating (e.g. white – blood) cells or cell-free DNA (cfDNA), derived from dying („turning-over”) cells – indeed such cfDNA is always entering the bloodstream, with a turnover half life of some minutes, before the body digests and recycles the constituents. What has recently been appreciated is that this last statement applies to cancer – fragments of cancer cfDNA are constantly entering the bloodstream, are detectable by NGS and can be differentiated from normal DNA by the mutational „fingerprint” – best detected by the ‚defining’ gains and losses (DNA Copy Number Instability score – CNI). The scientists at Chronix were the first to use NGS for human cfDNA in healthy(1) as well as cancer patients (2, 3).

Indeed, assessment of CNI may be the best test for determining the presence of cancer, the best test for determining whether treatments such as surgery have achieved a cure of a cancer and whether a past cancer is returning – by serial testing at intervals. More research on the cfDNA may allow us to determine the tissue of origin of the cancer e.g. prostate versus lung cancer, and for following the mutational evolution of a cancer, for cancer cells are mutating unceasingly during their natural history and oncologists nowadays can use drugs to block some specific driving oncogenes pathways-of therapeutic importance.

  1. Beck J, Urnovitz HB, Riggert J, Clerici M, Schütz E. Profile of the circulating DNA in apparently healthy individuals. Clin Chem 2009;55:730-8.
  2. Beck J, Urnovitz HB, Mitchell WM, Schütz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res 2010;8:335-42.
  3. Schütz E, Akbari MR, Beck J, Urnovitz H, Zhang WW, Bornemann-Kolatzki K, et al. Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. Clin Chem 2015;61:239-48.



Prof. Dr. med. Dr. h.c. Michael Oellerich


“The knowledge that we have gained over the past year now suggests to us that we are able to provide to doctors and their patients the ability to diagnose at the most earliest stage the presence of cancer in their body.”
Howard Urnovitz